GNI Group Ltd.
Notice Regarding FDA Approval of Accelagen™ Plus Surgical Matrix
BAB, a consolidated subsidiary, obtained FDA 510(k) clearance for Accelagen™ Plus Surgical Matrix, a private-brand product. Aiming to commence sales in the United States in Q1 2027, we are pursuing private-branding of the MedTech business. Minor impact on the consolidated results for the fiscal year ending December 2026.
Key Figures
- FDA approval of Accelagen™ Plus (510(k))
- U.S. sales start in Q1 2027
- Minor impact on 2026 consolidated results
AI要約
FDA approval of Accelagen Plus and business strategy
Consolidated subsidiary BAB has obtained FDA 510(k) clearance for the first private-brand product Accelagen™ Plus Surgical Matrix. By expanding the wound management portfolio with this new product, we will promote private-branding leveraging BAB's collagen and biomaterials technology. We aim to begin U.S. sales in Q1 2027, targeting profitability improvement and long-term growth of the MedTech business.
Upcoming sales launch and impact
U.S. sales are scheduled to commence in Q1 2027. Expanding the private-brand framework including ACCELAGEN Plus will support profitability and long-term growth of the MedTech business. This approval is described as accelerating BAB's expansion into the wound management field.
GNI Group Ltd.
Company overview · Stock price · Financial data · All IR
